Emma Helen Southgate

Title: **Innovative Contributions of Emma Helen Southgate**

Introduction

Emma Helen Southgate is a prominent inventor based in Mountain View, California. She has made significant strides in the field of pharmaceutical innovations, particularly in the development of compounds that address various metabolic diseases.

Latest Patents

Emma holds a patent for the "Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors." This patent includes a detailed description of compounds of Formula I and their pharmaceutically acceptable salts, esters, and prodrugs. These compounds serve as critical DGAT2 inhibitors and have potential applications for treating conditions such as hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, and cardiorenal diseases, among others.

Career Highlights

Emma has showcased her expertise through her work at Merck Sharp & Dohme Corporation, where she continues to push the boundaries of medical science. Her dedication to research has contributed significantly to advancements that can improve patient health outcomes and pave the way for novel therapeutic strategies.

Collaborations

Throughout her career, Emma has collaborated with notable colleagues, including Yeon-Hee Lim and Eric Ashley. These collaborations have further enhanced her research initiatives and have led to innovative discoveries in her field.

Conclusion

Emma Helen Southgate stands out as a notable inventor whose work on DGAT2 inhibitors has the potential to revolutionize treatments for various metabolic disorders. Her career exemplifies the impact of innovative thinking in the field of pharmaceuticals, and her contributions will likely continue to benefit patients in need of effective therapies.